Natera, Inc.
333.69
-0.00% (최근 종가 333.69)
Company profile — from Yahoo Finance
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Company information as provided by Yahoo Finance. Check the official filings before relying on it.
Market Cap
481억 달러
PER
-
Trailing 12 months
Forward P/E
-3743.7배
Forward estimates
ROE
-12.5%
Return on equity
Dividend Yield
-
Beta
1.51
Volatility vs market
52주 범위에서 99% 지점입니다. 100%에 가까울수록 1년 최고가 부근입니다.
Source: Yahoo Finance
Average analyst price target
범위 $280.00 ~ $375.00 · 애널리스트 21명 · 종합의견 적극 매수 · 출처 Yahoo Finance
Analyst rating breakdown (2026-08-01)
월가는 이 종목을 뚜렷한 매수 우위로 보고 있습니다. (매수 26 · 관망 4 · 매도 0)
Revenue trend
23억 달러
2022–2025 회계연도 · 축 단위는 달러입니다.
Net income trend
-2억 달러
2022–2025 회계연도 · 축 단위는 달러입니다.
| Year | Revenue | Operating Income | Net Income | Operating Cash Flow | Net Margin |
|---|---|---|---|---|---|
| 2025 | 23억 달러 | -3억 달러 | -2억 달러 | 2억 달러 | -9.0% |
| 2024 | 17억 달러 | -2억 달러 | -2억 달러 | 1억 달러 | -11.2% |
| 2023 | 11억 달러 | -4억 달러 | -4억 달러 | -2억 달러 | -40.2% |
| 2022 | 8억 달러 | -5억 달러 | -5억 달러 | -4억 달러 | -66.8% |
회계연도 기준 실적입니다(달력 연도와 다를 수 있습니다). 출처: Yahoo Finance. 값이 없는 항목은 채우지 않고 "-"로 둡니다.
SeekingAlpha · 08. 26.
SeekingAlpha · 08. 20.
SeekingAlpha · 08. 20.
Prices, key stats, price targets, annual financials, filings and news above come straight from Yahoo Finance · Finnhub · SEC EDGAR, so they look the same for any US-listed ticker.
Support & resistance shows above whenever my TradingView indicator is sending alerts for the ticker. No alert is set up for this one yet, so there are no levels.
Option levels · MJM Score · REAL_BUY signals come through a Google Sheet and are still limited to the fixed watchlist. We leave them out rather than guess.